The aggravation of inflammation and insulin resistance in the presence of LPS and CB1 agonists, and the attenuation of LPS inflammatory effects by CB1 inhibition allowed to conclude that blocking this receptor could lead to beneficial manipulation of metabolic endotoxemia [82] and to gut-barrier permeability [23]. The gene discussed is CNR1; the disease is Insulin resistance.